C3 and primary membranoproliferative glomerulonephritis: Recent research in the treatment of C3G and IC‐MPGN, including phase 2 and phase 3 clinical trials, has focused on two promising agents: iptacopan, a factor B inhibitor, and pegcetacoplan, a targeted C3 and C3b inhibitor.